Valuation: Novartis AG

Market Cap 277B 244B 231B 209B 393B 26,628B 395B 2,762B 1,066B 13,588B 1,041B 1,019B 43,647B P/E 2026 *
20.6x
P/E 2027 * 17.4x
Enterprise Value 309B 272B 257B 233B 438B 29,658B 441B 3,077B 1,187B 15,134B 1,160B 1,135B 48,615B EV / Sales 2026 *
5.35x
EV / Sales 2027 * 4.97x
Free-Float
91.66%
Yield 2026 *
2.98%
Yield 2027 * 3.11%
1 week+3.97%
Current month-3.14%
1 month-7.22%
3 months-6.70%
6 months-2.53%
Current year+7.63%
1 week 122.2
Extreme 122.2
129.38
1 month 117.32
Extreme 117.32
141.26
Manager TitleAgeSince
Chief Executive Officer 50 01/02/2018
Director of Finance/CFO - 16/03/2026
Compliance Officer 58 14/04/2025
Director TitleAgeSince
Director/Board Member 67 01/01/2015
Director/Board Member 69 01/01/2016
Director/Board Member 61 01/01/2016
Change 5-day change 1-year change 3-year change Capi.($)
+1.57%+3.97%+21.22% - 275B
+0.11%+2.76%+63.52%+115.51% 1,055B
+0.27%+0.73%+51.33%+73.10% 654B
+0.73%+0.88%+20.70%+73.89% 467B
-1.36%-0.39%+40.20%+41.03% 348B
+1.34%+5.47%+23.37%+31.30% 275B
-0.48%-0.06%+13.56%+12.36% 258B
+0.85%+8.42%+53.17%+55.45% 224B
+0.85%+1.40%+35.78%+101.47% 187B
-0.30%-10.41%-27.62%-61.04% 171B
Average +0.08%+0.74%+29.52%+49.23% 404.26B
Weighted average by Cap. -0.11%+1.32%+39.32%+69.05%

Financials

2026 *2027 *
Net sales 57.74B 50.78B 48.03B 43.56B 81.86B 5,542B 82.31B 575B 222B 2,828B 217B 212B 9,084B 61.39B 53.99B 51.06B 46.32B 87.04B 5,892B 87.52B 611B 236B 3,007B 230B 225B 9,658B
Net income 14.2B 12.48B 11.81B 10.71B 20.12B 1,362B 20.24B 141B 54.54B 695B 53.29B 52.14B 2,233B 15.75B 13.85B 13.1B 11.89B 22.33B 1,512B 22.46B 157B 60.52B 772B 59.14B 57.86B 2,478B
Net Debt 31.58B 27.77B 26.27B 23.82B 44.77B 3,031B 45.01B 314B 121B 1,547B 119B 116B 4,968B 27.89B 24.52B 23.19B 21.04B 39.53B 2,676B 39.75B 278B 107B 1,366B 105B 102B 4,387B
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
-
Date Price Change
28/09/26 €129.26 +1.57%
25/09/26 €127.26 +0.68%
24/09/26 €126.40 +0.77%
23/09/26 €125.44 +1.51%
22/09/26 €123.58 +0.67%
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
145.97USD
Average target price
152.43USD
Spread / Average Target
+4.42%

Quarterly revenue - Rate of surprise